Sorafenib therapy for hepatocellular carcinoma in an HIV-HCV coinfected patient: a case report.
OBJECTIVE
HIV and hepatitis C virus (HCV) share common modes of transmission, resulting in about 33% incidence of coinfection among people infected with HIV. The survival benefit from highly effective antiretroviral therapy (HAART) for HIV infection is resulting in an increased incidence of hepatocellular carcinoma (HCC) in this population. There are no reports to date regarding the coadministration of HAART and sorafenib for hepatocellular carcinoma.


METHODS
We report the case of a 42-year-old male patient coinfected with HIV and HCV who developed advanced HCC not amenable to curative therapy. The patient was treated with sorafenib, an oral multikinase inhibitor shown to lead to a longer median survival time and time to progression in patients with advanced HCC. Antiretroviral therapy was continued during sorafenib therapy.


RESULTS
The patient achieved a partial tumor response after 3 months and continued to respond at subsequent assessments. His serum alpha-fetoprotein normalized from 2,172 IU/ml to 2 IU/ml. He had durable stable disease after 23 months of therapy. Antiretroviral therapy was efficacious (CD4(+) lymphocyte count, 377/microl; HIV viremia, <50 copies/ml). The simultaneous administration of these therapies was well tolerated. No grade 3 or 4 toxicities were observed. Exacerbation of pre-existing hypertension, grade 2 diarrhea, and grade 1 skin reaction were observed.


CONCLUSIONS
This is the first report in which sorafenib has been successfully used to treat HCC in a patient with HIV-HCV coinfection.
Perboni
Giorgio
G
Infectious Disease Unit, bRadiology Unit, and cMedical Oncology Unit, C Poma Hospital, Mantova, Italy. giorgio.perboni@hotmail.it
Costa
Paolo
P
Fibbia
Giovanni Carlo
GC
Morandini
Barbara
B
Scalzini
Alfredo
A
Tagliani
Alberto
A
Cengarle
Rita
R
Aitini
Enrico
E
D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001557:Benzenesulfonates / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000821:virology*; D015897:Comorbidity; D015658:HIV Infections / Q000188:drug therapy / Q000473:pathology* / Q000821:virology; D017320:HIV Protease Inhibitors / Q000627:therapeutic use; D006526:Hepatitis C / Q000188:drug therapy / Q000473:pathology* / Q000821:virology; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000821:virology*; D008297:Male; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011725:Pyridines / Q000627:therapeutic use*; D012307:Risk Factors; D000077157:Sorafenib
D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D017320:HIV Protease Inhibitors; D010671:Phenylurea Compounds; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib